πŸ‡ΊπŸ‡Έ FDA
Patent

US 12116346

Human plasma kallikrein inhibitors

granted A61PA61P1/02A61P1/04

Quick answer

US patent 12116346 (Human plasma kallikrein inhibitors) held by BioCryst Pharmaceuticals, Inc. expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BioCryst Pharmaceuticals, Inc.
Grant date
Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61P, A61P1/02, A61P1/04, A61P11/04, A61P13/02